Novartis Partners with IBM Watson on Breast Cancer Initiative

June 6, 2017

Novartis is collaborating with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes. The companies will be exploring development of a cognitive solution that uses patient data and advanced analytical techniques to provide insights on the expected outcomes of breast cancer treatments.

According to Novarvtis, this collaboration will bring its expertise in breast cancer together with Watson, the first commercially available cognitive computing capability that is delivered through the cloud, and its skill in data analytics and machine learning. Watson is able to analyze high volumes of data, understand complex questions posed in natural language and propose evidence-based answers.

"Through this collaboration with IBM Watson Health, we will use real-world breast cancer data and cognitive computing to identify solutions that may help physicians better understand which therapy may be best for which patients or advise clinical practice guidelines, with the goal of improving patient outcomes and experiences," said Bruno Strigini, CEO, Novartis Oncology. "We hope this collaboration also uncovers care efficiencies that can be applied beyond breast cancer."   

"As the industry shifts toward value-based care, it's critical for clinicians to understand the real-world outcomes of therapeutics on subsets of their patients, and our goal ultimately is to put those insights into oncologists' hands," said Anil Jain, MD, chief medical informatics officer, IBM Watson Health. 

Read the Novartis release